Clinical Study On Prognostic Factors Of Immunotherapy For Non-small Cell Lung Cancer

Objective:To study the relationship between the factors,concluding the expression of programmed cell death ligand 1(PD-L1),lung immune prognostic index(LIPI),tumor mutation burden(TMB),lung cancer inflammatory index(ALI),and the efficacy and the prognosis of the patients who use immune checkpoint inhibitors(ICIs).Methods:This study included 84 cases of NSCLC patients who used ICIs monotherapy.We analysised the correlation between patients’ age,gender,height,weight,pathological type,clinical stage,PD-L1,TMB,LIPI,ALI and objective response rate(ORR),disease control rates(DCR),progression-free survival(PFS)and overall survival(OS).Results:Univariate analysis showed that clinical stage,the lines of treatment,PD-L1,TMB,LIPI,ALI were correlated with PFS and OS(P<0.05).Multivariate analysis showed that PD-L1,TMB,LIPI and clinical stage were correlated with PFS(P<0.05),while PD-L1,TMB,LIPI and the lines of treatment were correlated with OS(P<0.05).PD-L1,TMB,LIPI,ALI,clinical stage,the lines of treatment were correlated with objective response rate and disease control rate.Conclusion:PD-L1,TMB,LIPI,clinical stage and the lines of treatment can effectively predict the efficacy of NSCLC immunotherapy,which can has significance for clinical individualized drug use.